Instil bio inc
TIL 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
TIL 近期報酬表現
4.66%
Instil bio inc
1.19%
同產業平均
0.91%
S&P500
與 TIL 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
BFRG | Bullfrog ai holdings, inc. | - | 2 分 | 2 分 | - | 1 分 | |
CVKD | Cadrenal therapeutics inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
ME | 23andme holding co. | 2 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
VXRT | Vaxart inc | 4 分 | 2 分 | 1 分 | 1 分 | 1 分 | |
ERAS | Erasca inc | - | 3 分 | 3 分 | 2 分 | 1 分 |
- BFRG Bullfrog ai holdings, inc.價值 -趨勢 2 分波段 2 分籌碼 -股利 1 分查看更多
TIL 公司資訊
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.